Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Accumulated Expenses: 2020-2024

Historic Accumulated Expenses for Tango Therapeutics (TNGX) over the last 5 years, with Dec 2024 value amounting to $16.5 million.

  • Tango Therapeutics' Accumulated Expenses fell 12.61% to $13.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.1 million, marking a year-over-year decrease of 12.61%. This contributed to the annual value of $16.5 million for FY2024, which is 7.12% up from last year.
  • As of FY2024, Tango Therapeutics' Accumulated Expenses stood at $16.5 million, which was up 7.12% from $15.4 million recorded in FY2023.
  • Tango Therapeutics' Accumulated Expenses' 5-year high stood at $17.5 million during FY2022, with a 5-year trough of $6.1 million in FY2020.
  • Moreover, its 3-year median value for Accumulated Expenses was $16.5 million (2024), whereas its average is $16.5 million.
  • Per our database at Business Quant, Tango Therapeutics' Accumulated Expenses spiked by 76.95% in 2022 and then declined by 11.97% in 2023.
  • Yearly analysis of 5 years shows Tango Therapeutics' Accumulated Expenses stood at $6.1 million in 2020, then skyrocketed by 61.03% to $9.9 million in 2021, then spiked by 76.95% to $17.5 million in 2022, then fell by 11.97% to $15.4 million in 2023, then climbed by 7.12% to $16.5 million in 2024.